Profusa Goes Public on Nasdaq with Tissue-Integrating Biosensor Platform for Chronic Disease Management
核心洞察
Profusa (搜索), Inc. completed its business combination with NorthView Acquisition Corp. (搜索) and began trading on Nasdaq under ticker "PFSA" on July 14, 2025.
The Berkeley-based company has developed tissue-integrating biosensors that can function for months and continuously monitor body chemistry for diabetes (搜索), critical limb ischemia (搜索), and peripheral arterial disease (搜索) management.
The company raised $9 million through a secured convertible promissory note with up to $20 million available to support transaction costs and working capital needs.
Profusa (搜索), Inc., a commercial-stage digital health company developing tissue-integrating biosensors for continuous biochemical monitoring, completed its business combination with NorthView Acquisition Corp. (搜索) and began trading on Nasdaq under the ticker symbol "PFSA" on July 14, 2025. The transaction, approved by NVAC shareholders on June 9, 2025, marks a significant milestone for the Berkeley-based company's decade-long mission to transform chronic disease management through continuous monitoring technology.
Revolutionary Biosensor Technology Platform
Profusa (搜索) has developed a next-generation technology platform featuring tissue-integrating biosensors that can function for months at a time while continuously monitoring and transmitting body chemistry data to smartphone applications. The injectable biosensors are designed to provide long-lasting, affordable monitoring solutions that integrate with best-in-class data analytics and artificial intelligence technologies.
"We believe being a public company better positions us to advance our vision in pioneering tissue-integrating biosensors platform that could function for months at a time, with transformative lower costs, and continuously monitor and transmit body chemistries to smart phone applications," said Ben Hwang (搜索), Ph.D., Profusa (搜索)'s Chairman and CEO.
Clinical Applications and Target Conditions
The biosensor platform enables real-time actionable decisions for healthcare professionals and patients to improve general health management and treat chronic diseases. Specifically, the technology targets diabetes (搜索) management, critical limb ischemia (搜索) (CLI), and peripheral arterial disease (搜索) (PAD) monitoring applications.
The company's intelligent data platform aims to provide personalized biochemical signatures rooted in medical-grade data that clinicians can trust and rely on for patient care decisions. This approach represents a significant advancement in continuous monitoring technology, moving beyond traditional intermittent testing methods.
Financial Structure and Market Position
In connection with the business combination, Profusa (搜索) issued a secured convertible promissory note to an institutional investor, raising $9 million to cover transaction costs and support future working capital needs. The convertible note facility provides access to up to $20 million total funding.
The company's warrants will continue trading on the OTCID market rather than on Nasdaq. Multiple financial and legal advisors supported the transaction, including A.G.P./Alliance Global Partners, I-Bankers Securities, and Dawson James Securities as financial advisors to NVAC.
Commercial Stage Development
Profusa (搜索) describes itself as a commercial-stage digital health company led by visionary scientific founders, an experienced management team, and a world-class board of directors. The company has developed a new generation of tissue-integrated sensors designed to detect and continuously transmit actionable, medical-grade data for both personal and medical use.
The company's mission, which began over a decade ago, focuses on harnessing transformative science to positively impact quality of daily living and chronic disease management. Profusa (搜索) holds registered trademarks for "LUMEE," "PROFUSA," and the PROFUSA logo across multiple international markets, including the United States, Canada, European Union, China, Japan, South Korea, and Australia.